Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANGO AngioDynamics	$10.23 +0.7%	$9.76	$5.47 ▼ $13.50	$412.57M	0.62	580,803 shs	342,029 shs
ATRC AtriCure	$31.61 -3.0%	$32.53	$20.20 ▼ $43.11	$1.61B	1.59	633,788 shs	379,655 shs
IART Integra LifeSciences	$11.91 -2.0%	$14.10	$11.60 ▼ $32.66	$944.20M	1.16	1.05 million shs	1.27 million shs
OFIX Orthofix Medical	$10.35 -1.6%	$12.21	$10.25 ▼ $20.73	$412.18M	0.8	280,128 shs	1.01 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANGO AngioDynamics	+0.69%	-6.15%	+6.67%	+3.65%	+81.06%
ATRC AtriCure	-3.04%	-4.27%	-2.44%	-9.22%	+49.10%
IART Integra LifeSciences	-1.98%	-7.17%	-12.10%	-47.56%	-58.93%
OFIX Orthofix Medical	-1.62%	-9.05%	-14.18%	-38.76%	-19.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANGO AngioDynamics	4.1617 of 5 stars	3.5	2.0	4.2	3.2	1.7	0.6
ATRC AtriCure	3.6284 of 5 stars	4.5	3.0	0.0	2.3	2.5	0.6
IART Integra LifeSciences	4.4849 of 5 stars	3.9	1.0	4.0	1.9	1.7	2.5
OFIX Orthofix Medical	2.8308 of 5 stars	3.4	2.0	0.0	1.3	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANGO AngioDynamics	3.00	Buy	$14.00	36.85% Upside
ATRC AtriCure	3.00	Buy	$50.67	60.29% Upside
IART Integra LifeSciences	1.78	Reduce	$18.63	56.38% Upside
OFIX Orthofix Medical	2.75	Moderate Buy	$23.33	125.44% Upside

Current Analyst Ratings Breakdown

Latest OFIX, ATRC, IART, and ANGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	OFIX Orthofix Medical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/9/2025	IART Integra LifeSciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$35.00 ➝ $25.00
5/6/2025	IART Integra LifeSciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $13.00
5/6/2025	IART Integra LifeSciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$24.00 ➝ $12.00
4/30/2025	ATRC AtriCure	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$60.00 ➝ $60.00
4/30/2025	ATRC AtriCure	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $58.00
4/30/2025	ATRC AtriCure	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
4/11/2025	IART Integra LifeSciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$26.00 ➝ $19.00
4/7/2025	ANGO AngioDynamics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $16.00
3/31/2025	IART Integra LifeSciences	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/28/2025	ATRC AtriCure	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $52.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANGO AngioDynamics	$303.91M	1.37	$4.32 per share	2.37	$5.13 per share	1.99
ATRC AtriCure	$465.31M	3.36	N/A	N/A	$9.46 per share	3.34
IART Integra LifeSciences	$1.61B	0.57	$4.36 per share	2.73	$20.03 per share	0.59
OFIX Orthofix Medical	$799.49M	0.51	N/A	N/A	$13.07 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANGO AngioDynamics	-$184.35M	-$1.01	N/A	N/A	N/A	-14.61%	-3.73%	-2.43%	7/15/2025 (Estimated)
ATRC AtriCure	-$44.70M	-$0.81	N/A	N/A	N/A	-7.95%	-5.68%	-4.34%	7/29/2025 (Estimated)
IART Integra LifeSciences	-$6.94M	-$0.38	N/A	4.76	0.68	-1.78%	12.12%	4.58%	8/4/2025 (Estimated)
OFIX Orthofix Medical	-$126M	-$3.69	N/A	N/A	N/A	-17.78%	-28.15%	-16.51%	8/5/2025 (Estimated)

Latest OFIX, ATRC, IART, and ANGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/15/2025	Q4 2025	ANGO AngioDynamics	-$0.13	N/A	N/A	N/A	$74.26 million	N/A
5/5/2025	Q1 2025	IART Integra LifeSciences	$0.43	$0.41	-$0.02	-$0.33	$381.17 million	$382.65 million
4/29/2025	Q1 2025	ATRC AtriCure	-$0.25	-$0.14	+$0.11	-$0.14	$122.92 million	$123.62 million
4/2/2025	Q3 2025	ANGO AngioDynamics	-$0.13	$0.03	+$0.16	-$0.11	$70.30 million	$72.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANGO AngioDynamics	N/A	N/A	N/A	N/A	N/A
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
IART Integra LifeSciences	N/A	N/A	N/A	N/A	N/A
OFIX Orthofix Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANGO AngioDynamics	N/A	2.21	1.40
ATRC AtriCure	0.16	4.11	2.88
IART Integra LifeSciences	0.81	1.21	0.72
OFIX Orthofix Medical	0.38	2.71	1.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANGO AngioDynamics	89.43%
ATRC AtriCure	99.11%
IART Integra LifeSciences	84.78%
OFIX Orthofix Medical	89.76%

Insider Ownership

Company	Insider Ownership
ANGO AngioDynamics	5.40%
ATRC AtriCure	3.50%
IART Integra LifeSciences	3.54%
OFIX Orthofix Medical	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANGO AngioDynamics	760	40.61 million	38.41 million	Optionable
ATRC AtriCure	1,300	49.51 million	47.77 million	Optionable
IART Integra LifeSciences	4,396	77.71 million	74.96 million	Optionable
OFIX Orthofix Medical	1,616	39.18 million	38.67 million	Optionable

OFIX, ATRC, IART, and ANGO Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Has $1.18 Million Stock Position in Orthofix Medical Inc. (NASDAQ:OFIX)

June 18 at 3:40 AM | marketbeat.com

Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System

June 17 at 12:13 PM | finance.yahoo.com

Orthofix Medical (NASDAQ:OFIX) shareholders have endured a 67% loss from investing in the stock five years ago

June 17 at 12:13 PM | finance.yahoo.com

Orthofix Medical Inc. (NASDAQ:OFIX) Short Interest Up 43.4% in May

June 16 at 6:24 PM | marketbeat.com

Orthofix Medical (NASDAQ:OFIX) Upgraded by Wall Street Zen to "Hold" Rating

June 15, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Orthofix Medical (NASDAQ:OFIX) to "Hold"

June 14, 2025 | marketbeat.com

Wall Street Zen Downgrades Orthofix Medical (NASDAQ:OFIX) to Sell

June 7, 2025 | marketbeat.com

Orthofix Medical's (OFIX) Market Perform Rating Reaffirmed at JMP Securities

June 6, 2025 | marketbeat.com

Orthofix Medical Inc. (NASDAQ:OFIX) Director Purchases $24,570.00 in Stock

June 6, 2025 | insidertrades.com

Orthofix Medical Inc. (NASDAQ:OFIX) Short Interest Update

June 6, 2025 | marketbeat.com

Orthofix Reports Larger Than Expected Loss Per Share

June 5, 2025 | ryortho.com

Orthofix Medical Inc. (NASDAQ:OFIX) Director Alan Lee Bazaar Purchases 2,250 Shares

June 5, 2025 | marketbeat.com

Highridge Medical sells EBI bone healing division to focus on spine

June 5, 2025 | massdevice.com

Avista Healthcare Partners acquires Highridge Medical’s bone healing unit EBI

June 5, 2025 | pehub.com

Nuveen Asset Management LLC Cuts Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

June 4, 2025 | marketbeat.com

Millennium Management LLC Sells 33,052 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

June 1, 2025 | marketbeat.com

Orthofix in the headlines: 5 updates

May 23, 2025 | beckersspine.com

Orthofix Medical Inc. (NASDAQ:OFIX) Shares Sold by AWM Investment Company Inc.

May 23, 2025 | marketbeat.com

Paradigm Capital Management Inc. NY Has $43.40 Million Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

May 22, 2025 | marketbeat.com

Northern Trust Corp Buys 29,768 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

May 22, 2025 | marketbeat.com

Orthofix Medical Inc. (NASDAQ:OFIX) Shares Purchased by Soleus Capital Management L.P.

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OFIX, ATRC, IART, and ANGO Company Descriptions

AngioDynamics NASDAQ:ANGO

$10.23 +0.07 (+0.69%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$10.16 -0.07 (-0.72%)

As of 06/18/2025 04:59 PM Eastern

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

AtriCure NASDAQ:ATRC

$31.61 -0.99 (-3.04%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$31.60 0.00 (-0.02%)

As of 06/18/2025 06:18 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Integra LifeSciences NASDAQ:IART

$11.91 -0.24 (-1.98%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.92 +0.01 (+0.08%)

As of 06/18/2025 06:45 PM Eastern

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Orthofix Medical NASDAQ:OFIX

$10.35 -0.17 (-1.62%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$10.35 0.00 (0.00%)

As of 06/18/2025 06:41 PM Eastern

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time